Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
about
Human cytomegalovirus resistance to antiviral drugsCMV: Prevention, Diagnosis and TherapyHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsAntiviral drug resistance: mechanisms and clinical implicationsAntiviral drug resistance of human cytomegalovirus.Management of cytomegalovirus infection and disease in liver transplant recipients.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipientsCurrent concepts on cytomegalovirus infection after liver transplantationThe HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitroGanciclovir-resistant cytomegalovirus infection in renal transplantation.Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients.Epigenetically repressing human cytomegalovirus lytic infection and reactivation from latency in THP-1 model by targeting H3K9 and H3K27 histone demethylases.Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney TransplantsCytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir.Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.Strategies for managing cytomegalovirus in transplant recipients.Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.Cytomegalovirus infection and the gastrointestinal tract.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.De novo inflammatory bowel disease and its mimics after organ transplantation.Prevention of cytomegalovirus following solid organ transplantation: a literature review.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus.Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus InfectionTreatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.Risk Factors and Outcomes of Ganciclovir Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection.Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin.Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients.Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome.
P2860
Q24556634-E06B83B3-6394-4375-A71B-0BB1F18E32F9Q26824869-0EA9BD2B-2D9B-47B3-98E8-0E47DE28FDB4Q28069489-BC3B569F-7D10-4357-82CC-08011C7D9EFCQ28282376-AA4920B2-D6F6-4B77-9608-02E96297DFB2Q30430427-6C7E64DB-312A-4AB6-B6BB-1A827D0C2C5BQ33845124-5389A487-C92B-4866-9D08-D01F551D4DE1Q33932079-2E601778-C4CC-4685-9585-DEFC73489AECQ34390310-AD7169DB-B4D1-4321-B211-801499208687Q35005190-9E0EFAE6-DDCB-4A45-AA20-305D646E9AB3Q35227636-1704A178-2120-4AD1-B27E-F9C07147063CQ35598906-13BE6F2E-F7DD-4B59-BDE4-28A69F8412CAQ35692301-D099D347-FFEF-4900-B91B-469B2195437CQ35922545-8B1E7DA6-23D8-465F-B25E-0D4494034CC9Q36346073-1A9C6A88-80AD-437F-96C8-4286198E9F0AQ36514890-97D9EE8C-0B1F-461C-9CA6-9F5DD75EB332Q36728782-AB3E27F3-28AB-44C6-8A7E-7814FA5E5978Q37036531-D08F27E7-F0FC-42BB-AAE5-3D21A6201C59Q37222032-3D033D03-033A-4AE1-878D-8B6946CE66ACQ37409907-DDA4D36F-8002-49E2-A3BC-589089DC9CC7Q37544353-FA7541CC-6CFC-486A-84CD-6FE797031FCEQ37773992-2C2498E7-EFF4-4E59-BD84-D5D7F70850D0Q37962447-29BA4A2D-BB04-437F-A76C-08A221757700Q38010341-5F4E10D8-BF5C-467D-958B-3FD122F8F0CCQ38067694-3FBF83AA-0013-401C-B27D-AE963D4B6C63Q38105200-9672AA33-196B-40B4-BB99-3CEA2B734A7AQ38124439-1943856E-E333-47B0-98B4-5C0E65650D56Q38364698-9834E08B-B9FB-4130-A9E9-AA5A8EF07D41Q38415861-5413D5FD-22C5-4A6F-857E-679195ED59B1Q38664637-CB99340F-8BD7-43AB-AFDA-D5E6E48557C1Q38725677-4F74754C-63CB-4DF9-9955-53BB59AB5781Q38834042-3104E5FC-6BF5-43E6-BEE1-9BB2891CF549Q38875887-1CFABFB2-8FCA-49FA-95DE-9FC2E3101626Q39502888-090802ED-2F82-49E0-8B37-3BA4DF97D2A3Q40262029-5A816740-D3EC-4655-A697-FD75FCD6B826Q40426465-583F6CCD-98EF-40D7-B684-B7497E3C9326Q40483485-5B267D4A-8895-4D34-B0A4-FB2F9EBF462DQ40589966-32EAE464-937F-416F-9847-9BBB5C8E917CQ40745646-729C6A67-9361-4F15-B55D-19A170815E82Q41099858-524B8AD6-CA27-47F8-BED4-FC545F15251CQ41177320-BEEBF5EF-5018-4FC6-83E7-8D3C57647960
P2860
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@en
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@nl
type
label
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@en
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@nl
prefLabel
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@en
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@nl
P2860
P356
P1476
Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
@en
P2093
Ajit P Limaye
P2860
P304
P356
10.1086/342385
P407
P577
2002-09-10T00:00:00Z